US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
BR0213761A
(pt)
*
|
2001-10-25 |
2005-04-12 |
Genentech Inc |
Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
|
ES2500918T3
(es)
|
2001-12-21 |
2014-10-01 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina e interferón beta
|
AU2002364587A1
(en)
|
2001-12-21 |
2003-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20070161087A1
(en)
*
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
NZ543292A
(en)
*
|
2003-06-12 |
2008-04-30 |
Lilly Co Eli |
GLP-1 analog fusion proteins
|
EP1729795B1
(en)
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
PT1831252E
(pt)
*
|
2004-12-22 |
2009-09-17 |
Lilly Co Eli |
Formulações de proteínas de fusão de análogos de glp-1
|
EP1881850B1
(en)
*
|
2005-05-13 |
2010-09-29 |
Eli Lilly And Company |
Glp-1 pegylated compounds
|
EP1920061A4
(en)
*
|
2005-07-27 |
2009-05-13 |
Wang Qinghua |
GLP / 1 / EXENDIN 4 IGG FC FUSION CONSTRUCTS FOR THE TREATMENT OF DIABETES
|
CN101277722A
(zh)
|
2005-08-06 |
2008-10-01 |
王庆华 |
用于预防和治疗ⅰ型糖尿病的组合物及方法
|
ES2397289T3
(es)
*
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
|
EP1948785B1
(en)
*
|
2005-10-24 |
2014-01-15 |
Janssen Biotech, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
JP2009514900A
(ja)
|
2005-11-04 |
2009-04-09 |
スミスクライン・ビーチャム・コーポレイション |
血糖降下剤の投与方法
|
CA2628241C
(en)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
JP2009534423A
(ja)
|
2006-04-20 |
2009-09-24 |
アムジェン インコーポレイテッド |
Glp−1化合物
|
WO2008028117A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
US20110039776A1
(en)
*
|
2006-09-06 |
2011-02-17 |
Ashutosh Chilkoti |
Fusion peptide therapeutic compositions
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
KR101542752B1
(ko)
|
2006-12-22 |
2015-08-10 |
체에스엘 베링 게엠베하 |
연장된 생체내 반감기를 갖는 변형된 응고 인자
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
JP2008169195A
(ja)
*
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
SG177953A1
(en)
*
|
2007-01-05 |
2012-02-28 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
EP2109457B1
(en)
|
2007-02-12 |
2016-01-06 |
CSL Behring GmbH |
Therapeutic application of kazal-type serine protease inhibitors
|
NZ578948A
(en)
|
2007-02-15 |
2012-03-30 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
CA2680792A1
(en)
*
|
2007-03-15 |
2008-09-18 |
Biogen Idec Ma Inc. |
Treatment of autoimmune disorders
|
DK2172479T3
(en)
*
|
2007-06-19 |
2016-12-19 |
Glytech Inc |
GLP-1 peptide having the sugar chain attached thereto
|
US7960336B2
(en)
*
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
JP2010535781A
(ja)
*
|
2007-08-03 |
2010-11-25 |
イーライ リリー アンド カンパニー |
肥満に対する処置
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
EP2031064A1
(de)
*
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
JP5771005B2
(ja)
*
|
2007-10-30 |
2015-08-26 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物
|
US8981047B2
(en)
|
2007-10-30 |
2015-03-17 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
AU2009210570B2
(en)
*
|
2008-01-30 |
2014-11-20 |
Indiana University Research And Technology Corporation |
Ester-based insulin prodrugs
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
TWI541023B
(zh)
*
|
2008-06-17 |
2016-07-11 |
印第安納大學科技研究公司 |
在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
|
PE20100056A1
(es)
*
|
2008-06-17 |
2010-01-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon como agonistas gip
|
AR072160A1
(es)
|
2008-06-17 |
2010-08-11 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
RU2528855C2
(ru)
|
2008-06-24 |
2014-09-20 |
Цсл Беринг Гмбх |
Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
WO2010042747A2
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
JP2012512903A
(ja)
|
2008-12-19 |
2012-06-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
MX2011011815A
(es)
|
2009-05-05 |
2012-01-27 |
Amgen Inc |
Mutantes fgf21 y usos de los mismos.
|
JO3469B1
(ar)
|
2009-05-05 |
2020-07-05 |
Amgen Inc |
طافرات fgf21 واستخداماتها
|
IN2012DN00377A
(US07989598-20110802-C00006.png)
|
2009-06-16 |
2015-08-21 |
Univ Indiana Res & Tech Corp |
|
CA2764835A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
WO2011043530A1
(ko)
*
|
2009-10-09 |
2011-04-14 |
(주)알테오젠 |
Glp-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
|
JP2013512672A
(ja)
*
|
2009-12-02 |
2013-04-18 |
アムジエン・インコーポレーテツド |
ヒトFGFR1c、ヒトβ−クロト−、ならびにヒトFGFR1cおよびヒトβ−クロト−の両方に結合する結合タンパク質
|
UA109888C2
(uk)
*
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
WO2011094337A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
CA2793715A1
(en)
|
2010-04-30 |
2011-11-03 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
|
MX2012013005A
(es)
|
2010-05-13 |
2013-02-26 |
Univ Indiana Res & Tech Corp |
Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g.
|
JP6121323B2
(ja)
|
2010-05-13 |
2017-05-10 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
JP2013540102A
(ja)
|
2010-06-24 |
2013-10-31 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
|
EP2595647A1
(en)
*
|
2010-07-20 |
2013-05-29 |
Novo Nordisk A/S |
N-terminal modified fgf21 compounds
|
WO2012088116A2
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
KR20140016262A
(ko)
|
2011-01-14 |
2014-02-07 |
레드우드 바이오사이언스 인코포레이티드 |
알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
|
JP6109081B2
(ja)
|
2011-03-09 |
2017-04-05 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
人工表面との接触を含む医学的手技に伴う投与のためのfxii阻害剤
|
EP2497489A1
(en)
|
2011-03-09 |
2012-09-12 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
|
PT2691417T
(pt)
|
2011-03-29 |
2018-10-31 |
Roche Glycart Ag |
Variantes de fc de anticorpos
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
PE20140724A1
(es)
|
2011-06-22 |
2014-07-10 |
Univ Indiana Res & Tech Corp |
Coagonistas del receptor de glucagon/glp-1
|
KR102042982B1
(ko)
|
2011-07-22 |
2019-11-11 |
체에스엘 베링 게엠베하 |
억제성 항-xii/xiia 인자 모노클로날 항체 및 이들의 사용
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
KR20130049671A
(ko)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
생리활성 폴리펩타이드 결합체 제조 방법
|
CA2847246A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
ES2651523T3
(es)
|
2012-02-15 |
2018-01-26 |
Csl Behring Gmbh |
Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
|
JP6311708B2
(ja)
|
2012-06-21 |
2018-04-18 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gip受容体活性を示すグルカゴンアナローグ
|
HUE056217T2
(hu)
|
2012-07-13 |
2022-02-28 |
Roche Glycart Ag |
Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
JP6438397B2
(ja)
*
|
2012-09-12 |
2018-12-12 |
ジェンザイム・コーポレーション |
変更されたグリコシル化および低減されたエフェクター機能を有するFc含有ポリペプチド
|
CN104870019A
(zh)
|
2012-11-27 |
2015-08-26 |
阿特根公司 |
用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物
|
DK2925776T3
(en)
|
2012-11-27 |
2018-09-03 |
Biomarin Pharm Inc |
TARGETED THERAPEUTIC LYSOSOMAL ENZYMUS FUSION PROTEINS AND APPLICATIONS THEREOF
|
DK2964255T3
(da)
|
2013-03-08 |
2021-02-08 |
Csl Behring Gmbh |
Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
|
IL275376B2
(en)
|
2013-03-11 |
2024-01-01 |
Genzyme Corp |
Polypeptides with hyperglycosidic bonds
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
AU2014241743B2
(en)
|
2013-03-14 |
2018-07-05 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
ES2657291T3
(es)
|
2013-04-22 |
2018-03-02 |
Csl Ltd. |
Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
|
US20160166660A1
(en)
|
2013-06-28 |
2016-06-16 |
Csl Behring Gmbh |
Combination therapy using a factor xii inhibitor and a c-1 inhibitor
|
CN103408669B
(zh)
*
|
2013-08-01 |
2016-01-20 |
江苏泰康生物医药有限公司 |
Glp-1类似物融合蛋白,及其制备方法和用途
|
CN104592381A
(zh)
*
|
2013-10-31 |
2015-05-06 |
江苏万邦生化医药股份有限公司 |
一种利拉鲁肽中间体多肽的制备方法
|
WO2015138278A1
(en)
|
2014-03-11 |
2015-09-17 |
Novartis Ag |
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
|
CA2942769A1
(en)
|
2014-03-19 |
2015-09-24 |
Genzyme Corporation |
Site-specific glycoengineering of targeting moieties
|
JP2017511335A
(ja)
*
|
2014-03-31 |
2017-04-20 |
ハンミ ファーマシューティカル カンパニー リミテッド |
免疫グロブリンFcフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法
|
PL3157548T3
(pl)
|
2014-06-18 |
2022-01-17 |
Csl Behring Gmbh |
Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
|
JP6676551B2
(ja)
|
2014-07-02 |
2020-04-08 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
改変フォンウィルブランド因子
|
RS59789B1
(sr)
|
2014-07-21 |
2020-02-28 |
Delinia Inc |
Molekuli koji selektivno aktiviraju regulatorne t ćelije u tretmanima autoimunih bolesti
|
KR20170035910A
(ko)
|
2014-08-11 |
2017-03-31 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체
|
US10232020B2
(en)
|
2014-09-24 |
2019-03-19 |
Indiana University Research And Technology Corporation |
Incretin-insulin conjugates
|
CN104293834B
(zh)
*
|
2014-10-11 |
2018-03-23 |
上海兴迪金生物技术有限公司 |
GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
|
RU2729011C2
(ru)
|
2014-12-23 |
2020-08-03 |
Ново Нордиск А/С |
Производные fgf21 и их применения
|
KR101825048B1
(ko)
*
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
|
CR20170510A
(es)
|
2015-04-10 |
2018-02-26 |
Amgen Inc |
Muteínas de interuquina 2 para la expansión de células t regulatorias
|
AR105616A1
(es)
*
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
Proteínas de fusión
|
CA2986626A1
(en)
|
2015-05-22 |
2016-12-01 |
Csl Behring Recombinant Facility Ag |
Truncated von willebrand factor polypeptides for treating hemophilia
|
JP6651548B2
(ja)
|
2015-05-22 |
2020-02-19 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
改変フォン・ヴィルブランド因子を製造するための方法
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
RU2741345C2
(ru)
|
2015-10-28 |
2021-01-25 |
Юхан Корпорейшн |
Белки с двойной функцией и содержащая их фармацевтическая композиция
|
CA3003109A1
(en)
|
2015-10-28 |
2017-05-04 |
Yuhan Corporation |
Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
|
EP3184149A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Soluble glycoprotein v for treating thrombotic diseases
|
KR20180108602A
(ko)
|
2015-12-23 |
2018-10-04 |
암젠 인크 |
위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
|
US10806774B2
(en)
|
2016-01-07 |
2020-10-20 |
CSL Behring Lengnau AG |
Mutated truncated von Willebrand Factor
|
EP3400238B1
(en)
|
2016-01-07 |
2021-05-19 |
CSL Behring Lengnau AG |
Mutated von willebrand factor
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
KR20180132831A
(ko)
|
2016-04-06 |
2018-12-12 |
시에스엘 리미티드 |
죽상동맥경화증의 치료 방법
|
WO2017189432A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
US10336812B2
(en)
|
2016-05-10 |
2019-07-02 |
Janssen Biotech, Inc. |
GDF15 fusion proteins and uses thereof
|
WO2018032638A1
(zh)
|
2016-08-19 |
2018-02-22 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技(上海)有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
CN106317226B
(zh)
|
2016-08-19 |
2017-09-05 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
MX2019005380A
(es)
|
2016-11-10 |
2019-08-12 |
Yuhan Corp |
Composicion farmaceutica que comprende proteinas de fusion para prevenir o tratar la hepatitis, la fibrosis hepatica y la cirrosis hepatica.
|
CA3043397A1
(en)
|
2016-11-11 |
2018-05-17 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
|
TW201828975A
(zh)
|
2016-11-11 |
2018-08-16 |
瑞士商Csl貝林重組技能公司 |
用於治療血友病之截短型類血友病因子(von Willebrand factor)多肽類
|
EP3351262A1
(en)
|
2016-12-30 |
2018-07-25 |
Istanbul Universitesi Rektorlugu |
Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
WO2018194413A1
(en)
|
2017-04-21 |
2018-10-25 |
Yuhan Corporation |
Method for producing dual function proteins and its derivatives
|
RS64666B1
(sr)
|
2017-06-01 |
2023-11-30 |
Lilly Co Eli |
Dulaglutid za tretman hronične bolesti bubrega
|
WO2018234518A1
(en)
|
2017-06-22 |
2018-12-27 |
CSL Behring Lengnau AG |
MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ
|
KR20200054303A
(ko)
|
2017-09-22 |
2020-05-19 |
리제너론 파아마슈티컬스, 인크. |
글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도
|
AU2018372709B2
(en)
|
2017-11-21 |
2022-04-28 |
Eli Lilly And Company |
Methods of using and compositions containing dulaglutide
|
CN111518770B
(zh)
|
2017-12-19 |
2023-01-06 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
WO2019125003A1
(ko)
*
|
2017-12-22 |
2019-06-27 |
케이비바이오메드 주식회사 |
경구용 유전자 전달체 및 이의 용도
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
US11679143B2
(en)
|
2018-02-08 |
2023-06-20 |
Sunshine Lake Pharma Co., Ltd. |
FGF21 variant, fusion protein and application thereof
|
CA3106852A1
(en)
|
2018-07-19 |
2020-01-23 |
D&D Pharmatech Inc. |
Polypeptides and methods for treating disease
|
KR20200135618A
(ko)
|
2019-05-23 |
2020-12-03 |
㈜ 디앤디파마텍 |
폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
|
CN110878127B
(zh)
|
2018-09-06 |
2022-06-28 |
浙江柏拉阿图医药科技有限公司 |
长效重组GLP1-Fc-CD47蛋白及其制备和用途
|
CN111234000B
(zh)
*
|
2018-11-28 |
2023-05-26 |
鲁南制药集团股份有限公司 |
艾塞纳肽类似物
|
CN111269312B
(zh)
*
|
2018-12-04 |
2023-05-09 |
鲁南制药集团股份有限公司 |
一种异源融合蛋白质
|
CN109836486B
(zh)
*
|
2019-01-30 |
2020-09-08 |
北京双因生物科技有限公司 |
成纤维生长因子21变体、其融合蛋白及其用途
|
KR20210137093A
(ko)
*
|
2019-03-05 |
2021-11-17 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
폴리펩티드 분자 및 이의 적용
|
CA3131912A1
(en)
|
2019-03-08 |
2020-09-17 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
WO2020190591A1
(en)
|
2019-03-15 |
2020-09-24 |
Eli Lilly And Company |
Preserved formulations
|
CA3177693A1
(en)
|
2019-04-05 |
2020-10-05 |
Eli Lilly And Company |
Therapeutic uses of dulaglutide
|
KR20220009984A
(ko)
|
2019-05-17 |
2022-01-25 |
유니베르시태트 취리히 |
출혈성 뇌졸중 후 2차 신경학적 이상 반응을 치료하는데 사용하기 위한 합토글로빈
|
CN114072420A
(zh)
|
2019-07-04 |
2022-02-18 |
康诺贝林伦瑙有限公司 |
用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
|
MX2022004311A
(es)
|
2019-10-15 |
2022-05-10 |
Lilly Co Eli |
Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
|
WO2021094344A1
(en)
|
2019-11-11 |
2021-05-20 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
WO2021139744A1
(en)
|
2020-01-11 |
2021-07-15 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Conjugates of fusion proteins of glp-1 and fgf21
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
US20230372539A1
(en)
|
2020-08-24 |
2023-11-23 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
CN114106194B
(zh)
*
|
2020-08-31 |
2024-01-16 |
中国科学院天津工业生物技术研究所 |
一种用于治疗糖尿病和/或肥胖症的融合蛋白
|
CN116568327A
(zh)
|
2020-11-20 |
2023-08-08 |
德国杰特贝林生物制品有限公司 |
治疗抗体介导的排斥反应的方法
|
CN114685644A
(zh)
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
一种人glp-1多肽变体及其应用
|
EP4284407A1
(en)
|
2021-02-01 |
2023-12-06 |
CSL Behring AG |
Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
|
CA3217518A1
(en)
|
2021-05-07 |
2022-11-10 |
Rebecca Butcher |
Expression system for producing a recombinant haptoglobin (hp) beta chain
|
EP4368636A1
(en)
|
2021-07-06 |
2024-05-15 |
Suzhou Alphamab Co., Ltd. |
Fusion protein and application thereof
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|
CN114774496B
(zh)
*
|
2022-06-21 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
一种高密度发酵制备glp-1类似物的方法
|
WO2024047219A1
(en)
|
2022-09-02 |
2024-03-07 |
Csl Behring Ag |
Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
|
WO2024064842A1
(en)
|
2022-09-21 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating obesity, diabetes, and liver dysfunction
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|